Holen Sie sich die Stockscreener-App
0.013
6.56%
0.0008
Schlusskurs vom Vortag:
$0.0122
Offen:
$0.013
24-Stunden-Volumen:
3,556
Relative Volume:
0.06
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+8.33%
1M Leistung:
-9.72%
6M Leistung:
-67.42%
1J Leistung:
-76.41%
1-Tages-Spanne:
$0.0118
$0.0131
1-Wochen-Bereich:
$0.011
$0.025
52-Wochen-Spanne:
$0.005
$0.10
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
Firmenname
Nls Pharmaceutics Ag
Sektor
Branche
Telefon
41 44 512 21 50
Adresse
The Circle 6, Zurich
Vergleichen Sie NLSPW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.0131 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.04 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.85 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
667.95 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.45 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.10 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ag Aktie (NLSPW) Neueste Nachrichten
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga
NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - Marketscreener.com
SEC Form 425 filed by NLS Pharmaceutics Ltd. - Quantisnow
Pre-market Movers: HSDT, PBM, MTEM, APTO... - RTTNews
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S - Quantisnow
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - PR Newswire
NLS Pharmaceutics and Kadimastem eye January merger - Investing.com
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Advances Revolutionary Type 1 Diabetes Treatment, Seeks FDA Pre-IND Meeting - StockTitan
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India
NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria
NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India
NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com UK
NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire
NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan
NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com
NLS Pharmaceutics sets terms for $1M private placement By Investing.com - Investing.com Australia
NLS Pharmaceutics sets terms for $1M private placement - Investing.com
NLS Pharmaceutics reports preclinical data supporting dual orexin receptor agonists - BioWorld Online
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa
NLS Pharmaceutics reveals promising preclinical data By Investing.com - Investing.com Nigeria
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges - Investing.com
NLS Pharmaceutics reveals promising preclinical data - Investing.com
NLS Pharmaceutics announces preclinical data on DOXA platform - TipRanks
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Reports Breakthrough in Sleep-Wake Drug Development | NLSPW Stock News - StockTitan
NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
Finanzdaten der Nls Pharmaceutics Ag-Aktie (NLSPW)
Es liegen keine Finanzdaten für Nls Pharmaceutics Ag (NLSPW) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
2.45%
Kapitalisierung:
|
Volumen (24h):